MedTrace Logo

Study of APD421 With and Without Ondansetron

NCT03583489 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-10-01

No results posted yet for this study

Summary

Collection of pharmacokinetic and electrocardiograph data from healthy volunteers given APD421 +/- ondansetron

Conditions

  • Postoperative Nausea and Vomiting

Interventions

DRUG

APD421

10 mg IV

DRUG

Placebo

IV

DRUG

Ondansetron

4 mg IV

Sponsors & Collaborators

  • Acacia Pharma Ltd

    lead INDUSTRY

Principal Investigators

  • Muna Albayaty · Early Phase Clinical Unit

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-17
Primary Completion
2018-08-13
Completion
2018-08-13
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03583489 on ClinicalTrials.gov